Collaborative Research and Development Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Revenue Recognition [Abstract]

Schedule of Milestones Achieved

Milestones recognized through December 31, 2021 under the GSK Agreement are as follows:

	Anti-PD-1 (JEMPERLI/Dostarlimab)		Anti-TIM-3 (GSK4069889A/Cobolimab)		Anti-LAG-3 (GSK40974386)
Milestone Event	Amount	Quarter Recognized	Amount	Quarter Recognized	Amount	Quarter Recognized
Initiated in vivo toxicology studies using good laboratory practices (GLPs)	$1.0M	Q2'15	$1.0M	Q4'15	$1.0M	Q3'16
IND clearance from the FDA	$4.0M	Q1'16	$4.0M	Q2'16	$4.0M	Q2'17
Phase 2 clinical trial initiation	$3.0M	Q2'17	$3.0M	Q4'17	$3.0M	Q4'19
Phase 3 clinical trial initiation - first indication	$5.0M	Q3'18	—	—	—	—
Phase 3 clinical trial initiation - second indication	$5.0M	Q2'19	—	—	—	—
Filing of the first BLA(1) - first indication	$10.0M	Q1'20	—	—	—	—
Filing of the first MAA(2) - first indication	$5.0M	Q1'20	—	—	—	—
Filing of the first BLA - second indication	$10.0M	Q1'21	—	—	—	—
First BLA approval - first indication	$20.0M	Q2'21	—	—	—	—
First MAA approval - first indication	$10.0M	Q2'21	—	—	—	—
First BLA approval - second indication	$20.0M	Q3'21	—	—	—	—

(1) Biologics License Application (“BLA”)

(2) Marketing Authorization Application (“MAA”)

Milestones achieved through December 31, 2021 under the BMS Agreement are as follows:

	Anti-PD-1 (CC-90006)
Milestone Event	Amount	Quarter Recognized
Completion of first in vivo toxicology studies using GLPs	$0.5M	Q2'16
Phase 1 clinical trial initiation	$1.0M	Q4'16